home / stock / avte / avte articles
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in J...
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial h...
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE: ZGN) fell sharply du...
News, Short Squeeze, Breakout and More Instantly...
Aerovate Therapeutics Inc. Company Name:
AVTE Stock Symbol:
NASDAQ Market:
Aerovate Therapeutics Inc. Website:
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the I nhaled i M atinib P ulmonary A rterial H ypertension C linical T rial (IMPA...
A look at the top 10 most actives in the United States Mustang Bio Inc. (MBIO) rose 476.9% to $0.75 on volume of 1,104,730,765 shares NVIDIA Corporation (NVDA) fell 0.7% to $130.98 on volume of 283,604,651 shares ENDRA Life Sciences Inc. (NDRA) rose 34.2% to $0.139 on volume of 219,783,92...